Linnaeus Therapeutics LLC
LNS8801, a first-in-class GPER agonist small molecule therapeutic
- Sector
- Biotech
- Headquarters
- Philadelphia, PA
- Founded
- 2015
- Latest Form D
- $4.5M, Feb 2026
- Total capital
- $31.7M
- Federal grants
- $12.6M
- 9 awards · 2018–2026
- Rank in peer group#207 of 514
- Private capital raised
- $19.1M
- 7 Form D · last Feb 2026
- 8 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 11 pending · first 2021
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy$1.0M
- Private capital raisedForm D · SEC · 7th filing$4.5M
- Private capital raisedForm D · SEC · 6th filing$1.3M
- Federal grantHealth and Human S · Phase II · Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy$1.0M
- Private capital raisedForm D · SEC · 5th filing$1.6M
- Federal grantHealth and Human S · Phase II · Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma$2M
- Private capital raisedForm D · SEC · 4th filing$3.1M
- Private capital raisedForm D · SEC · 3rd filing$4.3M
- Private capital raisedForm D · SEC · 2nd filing$2.2M
- Private capital raisedForm D · SEC · 1st filing$2.2M
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma$4M
- Federal grantHealth and Human S · Phase II · Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma$2M
- Federal grantHealth and Human S · Phase II · Development of GPER Agonists as Cancer Therapeutics$1M
- Federal grantHealth and Human S · Phase II · Development of GPER Agonists as Cancer Therapeutics$1M
- Federal grantHealth and Human S · Phase I · Development of GPER agonists as Cancer Therapeutics$300K
- Federal grantHealth and Human S · Phase I · Development of GPER agonists as Cancer Therapeutics$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
6months
from Linnaeus Therapeutics LLC’s first federal award to its first private round.
- First federal award · Mar 2018
- Health and Human S · $300K
- First Form D · Sep 2018
- $2.2M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#207 · top 40%
- Granted patents#142 · top 28%
- Linked publications#46 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Christopher D. NataleResearcherExecutive OfficerLinked by 2 patents
- Chris ArendtDirectorNamed in SEC Form D filings
- Jack T. LeppingDirectorNamed in SEC Form D filings
- James T. DemetriadesDirectorNamed in SEC Form D filings
- John LeppingDirectorNamed in SEC Form D filings
- Michael PoiselDirectorNamed in SEC Form D filings
Show all 9 people
- Nicholas D. IatropoulosDirectorNamed in SEC Form D filings
- Patrick MooneyExecutive Officer, DirectorNamed in SEC Form D filings
- Todd T. ThomsonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 13- PendingEnantiomerically Purified Gper Agonist For Use In Treating Disease States And ConditionsUSPTOApplication 18752146
- PendingOncologic Variations Associated With Cancer And Methods Of TreatmentUSPTOApplication 18554260
- PendingDiagnostic Methods And Compositions For Treatment Of CancerUSPTOApplication 18561965
Show all 13 patent records
- Enantiomerically Purified Gper Agonist For Use In Treating Disease States And ConditionsMay 29, 2025 · Application 18752146Pending
- Oncologic Variations Associated With Cancer And Methods Of TreatmentNov 14, 2024 · Application 18554260Pending
- Diagnostic Methods And Compositions For Treatment Of CancerJul 25, 2024 · Application 18561965Pending
- Enantiomerically Purified Gper Agonist For Use In Treating Disease States And ConditionsNov 30, 2023 · Application 18364690Pending
- Enantiomerically Purified Gper Agonist For Use In Treating Disease States And ConditionsSep 19, 2023 · US 11,760,749Granted
- Enantiomerically Purified Gper Agonist For Use In Treating Disease States And ConditionsMar 24, 2022 · Application 17328590Pending
- Enantiomerically Purified Gper Agonist For Use In Treating Disease States And ConditionsMar 2, 2021 · US 10,934,277Granted
- Enantiomerically Purified Gper Agonist For Use In Treating Disease States And ConditionsJan 23, 2020 · Application 16518516Pending
- Enantiomerically Purified Gper Angonist For Use In Treating Disease States And ConditionsApplication 62701726Pending
- Oncologic Variations Associated With Cancer And Methods Of TreatmentApplication PCTUS2022023768Pending
- Diagnostic Methods And Compositions For Treatment Of CancerApplication 63190484Pending
- Oncologic Variations Associated with Cancer and Methods of TreatmentApplication 63172485Pending
- Enantiomerically Purified Gper Agonist For Use In Treating Disease States And ConditionsApplication PCTUS2019042827Pending
Recent research by its founders
- LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development20258 cites
- Data from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development20250 cites
- Figure 1 from LNS8801: An Enantiomerically Pure Agonist of the G Protein–Coupled Estrogen Receptor Suitable for Clinical Development20250 cites
Related companies, and why
- Inflection MedicineSimilar federal contract value in Biotech · null in contracts
- TenvieSimilar federal contract value in Biotech · null in contracts
- Aplexis, Inc.Similar federal contract value in Biotech · null in contracts
- TARGETSITE THERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
- C2N DIAGNOSTICS LLCSimilar federal contract value in Biotech · null in contracts
- I Peace, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .